2011 has been a resounding success for OncoSec, and 2012 is shaping up to be a pivotal year. Over this last year OncoSec has established a robust clinical development plan based on its novel, first-in-class OMS ElectroImmunotherapy treatment platform for the treatment of rare and deadly skin cancers, including (1) metastatic melanoma; (2) Merkel cell carcinoma; and (3) cutaneous T-cell lymphoma. In conjunction, the company has continued to create value from its advanced-stage OMS ElectroChemotherapy program for the treatment of primary and recurrent localized solid tumors, by analyzing a database of over 400 patients and presenting preliminary results of its Phase I/II breast cancer and preliminary Phase IV skin and head and neck cancer studies.
This year our management has laid out a focused corporate strategy, which was communicated with our shareholders in a recent press release. Complete detail of the Company’s key goals for 2012 can be found using this link.
One of the Company’s goals for 2011 was to increase OncoSec’s visibility in the scientific and investment community. Since our inception in March 2011, we feel that we have achieved this goal, however, it is an effort that we continue to make a priority to ensure that our the urgency of our message of revolutionizing targeted cancer therapy to treat rare and deadly skin cancers is continually voiced for the benefit of those who continue to suffer for these diseases, while still have little treatment options available to them. As a result of our public relations efforts has established a robust social media strategy through Facebook, Twitter and Linkedin, where we hope to reach a broad audience. In addition, OncoSec has been featured in a number of news and journal articles with the most recent being in Drug Discovery News where our President and CEO, Punit Dhillon, contributed an article outlining cutting-edge strategies for the treatment of solid tumors. As 2012 progresses, you can look forward to finding more articles about OncoSec and our revolutionary OMS ElectroOncology therapies.
If you have any questions about OncoSec or our current activities, please contact us at email@example.com. Thank you for your support
President & CEO